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The Dissociation of Gefitinib 
Trough Concentration and Clinical 
Outcome in NSCLC Patients with 
EGFR Sensitive Mutations
Shuang Xin1,*, Yuanyuan Zhao2,*, Xueding Wang1, Yan Huang2, Jing Zhang3, Ying Guo4, 
Jiali Li1, Hongliang Li1, Yuxiang Ma2, Lingyan Chen1, Zhihuang Hu2, Min Huang1 & Li Zhang2
Gefitinib is an essential drug for NSCLC patients harboring EGFR sensitive mutations. The approved 
dose 250mg/day is based on limited clinical trials, this research aims to explore the relationship 
between drug exposure and gefitinib response. Ctrough of 87 NSCLC patients harboring EGFR sensitive 
mutations were determined by LC-MS/MS. The median of Ctrough was 173.9 ng/ml (P25–P75, 130.5–
231.2 ng/ml), and cutoff value 200 ng/ml was determined by X-Tile. The PFS between Ctrough < 200 ng/
ml and Ctrough ≥ 200 ng/ml groups were not significantly different (17.3 VS 14.8 months; p = 0.258). 
Ctrough was not significantly associated with rash, diarrhea and hepatotoxicity. Non-smokers enjoyed 
longer PFS than smokers (18.7 VS 9.3 months; p = 0.025). The results showed that, for NSCLC 
patients with EGFR sensitive mutations, the PFS in lower trough concentration group were not 
inferior to that in higher trough concentration group and dose reduction is a rational suggestion 
for adjustment of dose regimen for aforementioned patients. More clinical trials are warranted to 
explore the precision dose schedule of gefitinib.
Gefitinib is an oral, reversible, tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor 
(EGFR) that plays a key role in the biology of non small cell lung cancer (NSCLC). For patients with 
advanced NSCLC harboring EGFR-TKI sensitive mutations, using EGFR-TKI as first-line treatment, 
progression-free survival (PFS) was reported to be two to three times better than platinum-doublet 
chemotherapy1–3. Based on these results, EGFR-TKIs monotherapy has become a standard regimen for 
advanced NSCLC with EGFR mutations.
However, several questions need to be addressed regarding the approved dosage regimen (250mg/
day) established based on limited clinical trials. According to the results of Iressa Dose Evaluation in 
Advanced Lung Cancer trial ı and trial ıı (IDEAL-1 and IDEAL-2), the doses 250 mg/day and 500 mg/
day have comparable response rate in all the NSCLC patients4,5. Meanwhile, recently, a post hoc anal-
ysis from NEJ002 was conducted to examine the efficacy of dose-reduction gefitinib compared with 
that of standard-dose gefitinib in EGFR-mutated NSCLC patients. In this research, a dose reduction of 
gefitinib by changing the everyday schedule to every 2 days schedule was permitted when grade ıı tox-
icity was observed. Interestingly, the low-dose group showed not-inferior efficacy (response and survival) 
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compared with standard-dose group6. However, Ichihara E. et al. reported that in EGFR-mutated NSCLC 
patients, PFS of the subjects with higher BSA was significantly worse than that of those with lower BSA 
and consequently postulated that blood concentrations were reversely correlated with BSA and then 
influenced the gefitinib response7. The postulations from Ichihara E.’s research are in contradiction with 
aforementioned clinical trials. To date, no study has been systemically conducted yet about the relation-
ship between the gefitinib PKs and its effects in NSCLC patients with EGFR mutation. The dose regimen 
of 250 mg/day has not been optimized for this specific group of NSCLC patients.
Recently, the concept of “precision medicine” has been raised up to further discover inter-individual 
difference of therapy outcomes and provide the best available care for each individual8. For gefitinib, as 
aforementioned, available data to verify the relationship between dosage regimen, blood exposure and 
drug effects are limited in NSCLC patients with EGFR sensitive mutations. The objective of this study 
was to retrospectively explore the relationship between gefitinib trough concentration, and clinical out-
comes in both efficacy and safety in patients carrying EGFR sensitive mutations.
Results
Patients’ characteristics. In total, 87 patients were included in the final analysis. Patient character-
istics were summarized in Table 1. 80 patients had major EGFR mutations (exon 19 deletions or exon 21 
L858R), 7 patients carried other sensitizing-mutations, such as exon 21 L861Q, exon 20 frame insertion. 
The median BSA was 1.66 m2 (range, 1.26–2.06 m2). The median age was 56 years (range, 29–79). The 
number of male and female was roughly comparable. Most patients had good PS (performance status) 
and carried adenocarcinoma histology. 23 (26%) patients were post-operatively relapsed patients. 24 
(28%) patients were former or current smokers. 9 patients (10%) suffered from CNS metastases after 
gefitinib administration. Table  2 compared the characteristics of the patients who were treated with 
gefitinib in the first-line setting with those in the later-line setting.
Association between clinicopathologic features and gefitinib trough concentration. The 
median of gefitinib trough concentration is 173.9 ng/ml (P25–P75, 130.5–231.2 ng/ml). For clinicopatho-
logic features such as gender, BSA, PS, smoker, CNS metastases and age, no factor was significantly 
correlated with gefitinib trough concentration (Table  3). The association between the BSA and trough 
concentration was analyzed by Spearman rank correlation test, rs = − 0.112 (P = 0.320). Gefitinib trough 
concentration was not correlated with CNS metastases. (Spearman rank correlation test, rs = − 0.142, 
P = 0.194).
Relationship between gefitinib trough concentration and objective response, progression-free 
survival. The objective response (complete response or partial response [PR]) rate is 57.5%. The dis-
ease control (complete response, partial response [PR] or stable disease [SD]) rate is 93.1%. In univari-
ate analysis, gefitinib trough concentration was not a predictor of objective response. The log-rank test 
was used to compare progression-free survival in each subset of patients (Table  4). The PFS between 
Ctrough < 200 ng/ml and Ctrough ≥ 200 ng/ml were not significantly different (17.3 VS 14.8 months; 
p = 0.258, Fig. 1).
Relationship between clinicopathologic features and objective response, progression-free 
survival. In univariate analysis, no factors were strong predictors of objective response. In log-rank 
Characters No. of patients
EGFR mutation status 37/43/7
(exon19 deletions/exon21 L858R/other 
sensitive mutations) 
Median BSA, m2 (range) 1.66 (1.26–2.06)
Median age, years (range) 56 (29–79)
Smoker (smoker/non-smoker) 24/61
Gender (male/female) 47/40
Staging (recurrence/ ııı B or ıV) 23/64
ECOG PS (0–1/2–3) 87/0
Histology (Ad /non-ad) 80/7
CNS metastases 9/77
Table 1.  Patients’ characteristics.
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test, non-smokers enjoyed longer progression-free survival than smokers (18.7 VS 9.3 months; p = 0.025, 
Fig. 2, Table 4).
Correlation between gefitinib trough concentration and toxicity. In binary logistic regression, 
trough concentration did not significantly associate with rash, diarrhea and hepatotoxicity (Table 5).
Discussion
Gefitinib is a standard therapy for NSCLC patients with EGFR sensitive mutations, however, few clinical 
trials have been conducted to discuss the association between gefitinib exposure and drug effect. Until 
now, whether the approved dose 250 mg/day is a rational dose schedule in patients with EGFR sensitive 
mutations remains disputable. We undertook this retrospective research to evaluate the impact of phar-
macokinetic factors on gefitinib drug effect and adverse drug reaction in NSCLC patients with EGFR 
sensitive mutations. Our results indicated that, for patients with EGFR sensitive mutations, after using 
gefitinib 250 mg/day, the progression-free survival of Ctrough < 200 ng/ml group were not inferior to that 
in higher trough concentration (Ctrough  ≥ 200 ng/ml) group. Meanwhile, trough concentration was not 
significantly associated with the adverse effects, including skin rash, diarrhea and hepatotoxicity. What’s 
more, non-smokers enjoyed better progression free survival. To our knowledge, this research provides 
the first evidence that the inter-patient pharmacokinetic variability is not the major cause of variation in 
gefitinib responses in patients with EGFR sensitive mutations.
One of the characteristics for molecularly targeted anticancer agents, the dose and response in efficacy 
and safety are not tightly correlated9,10. Regarding to gefitinib, 250 mg/day had a comparable response 
rate to 500 mg/day and milder adverse effects, in the Iressa Dose Evaluation in Advanced Lung Cancer 
(IDEAL-1 and  –2) trials4,5. The results from NEJ002 study are similar, in which the progression-free 
Characters Total (%)
First-line 
setting (%)
Later-line 
setting (%) P*
All patients 87 (100) 53 (61) 34 (39)
EGFR mutation status
exon19 deletions 37 (42) 19 (36) 18 (53) 0.235
exon21 L858R 43 (49) 30 (57) 13 (38)
other sensitizing-mutations 7 (9) 4 (7) 3 (9)
Gender
Male 47 (54) 27 (51) 20 (59) 0.514
Female 40 (46) 26 (49) 14 (41)
BSA,m2
< 1.66 40 (49) 24 (49) 16 (50) 1.000
≥ 1.66 41 (51) 25 (51) 16 (50)
Age, year
< 60 51 (59) 28 (53) 23 (68) 0.189
≥ 60 36 (41) 25 (47) 11 (32)
Smoker
Smoker 24 (28) 11 (21) 13 (39) 0.086
Non-smoker 61 (72) 41 (79) 20 (61)
Staging 
Recurrence 23 (26) 12 (23) 11 (32) 0.331
ııı B or  ıV 64 (72) 41 (77) 23 (68)
Histology
Adenocarcinoma 80 (92) 51 (96) 29 (85) 0.105
Non-adenocarcinoma 7 (8) 2 (4) 5 (15)
CNS metastases
CNS metastases 9 (10) 7 (13) 2 (6) 0.472
 Non-CNS metastases 77 (90) 46 (87) 31 (94)
Table 2.  The characteristics for qualitative variables of the patients treated with gefitinib in the first-
line setting and in the later-line setting. *Chi-square test and Fisher’s exact test, when there were fewer 
than five expected counts in the contingency table.
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survival and overall survival of dose-reduction group tended to be better, or at least similar to those 
of the standard-dose group6. Our results further confirmed this phenomenon. Recently, a retrospective 
study, focused on the relationship between BSA and PFS, demonstrated that for patients harboring EGFR 
mutations, the median PFS of the patients with higher BSA (≥ 1.5 m2) was significantly worse than that of 
those with lower BSA (< 1.5 m2) (10.4 VS 18.0 months; p = 0.019, log-rank test). The authors postulated 
that blood concentrations were reversely correlated with BSA and then influenced the gefitinib response7. 
However, this postulation has not been confirmed in our study. In our research, the BSA and trough 
concentration were not significantly correlated.
Further, both preclinical and clinical research revealed that the concentrations of gefitinib in tumor 
and skin were much higher than plasma concentrations in xenograft mice and patients, indicating poten-
tial tissue concentration of gefitinib9–11. In this research, the trough concentration ranged from 34.0 ng/
mL to 503.0 ng/mL. According to literature, the ratio of tumor concentration to plasma concentration 
ranged from 1.12~250 to 1 (median 40 to 1), which demonstrated tremendous interindividual varia-
bility12. Haura EB et al. reported that the lowest tumor concentration detected in operative tumor was 
3.638 μ M12, which was much higher than gefitinib IC50 for growth in cell lines with EGFR sensitive 
mutations (gefitinib IC50 for H3255 cell lines = 0.04 μ M)13. Consistent with the results from IDEAL1 and 
IDEAL2 clinical trials, our research further proved that, in patients with EGFR sensitive mutations, once 
plasma levels adequate to block tyrosine kinase have been achieved, additional plasma concentration 
escalations are unlikely to improve response.
Our research showed that non-smokers enjoyed longer PFS for patients with EGFR sensitive muta-
tions. This is consistent with the results from several randomized trials1,14,15. Whole genome sequenc-
ing analyses have shown that lung cancer due to tobacco smoking was associated with a significant 
Characters rs Pa
EGFR mutation status 0.076 0.485
exon19 deletions
exon21 L858R
other sensitizing-mutations
Gender − 0.102 0.347
Male
Female 
BSA,m2 − 0.112 0.320
< 1.66
≥ 1.66
Age, year 0.077 0.478
< 60
≥ 60
Smoker − 0.028 0.831
Smoker 
Non-smoker
Staging − 0.065 0.551
Recurrence
ıııB or ıV 
Histology − 0.165 0.127
Adenocarcinoma 
Non-adenocarcinoma 
Line 0.174 0.106
First-line setting
Later-line setting
CNS metastases − 0.142 0.194
CNS metastases
Non-CNS metastases
Table 3.  Correlation between clinicopathologic features and gefitinib trough concentration *P <  0.05; 
aSpearman rank correlation test.
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Characters Univariate analysis Pa
Trough concentration 0.258
C < 200 ng/ml
C ≥ 200 ng/ml
EGFR mutation status 0.743
exon19 deletions
exon21 L858R
other sensitizing-mutations
Gender 0.717
Male
Female 
BSA, m2 0.591
< 1.66
≥ 1.66
Age, year 0.483
< 60
≥ 60
Smoker 0.025*
Smoker
Non-smoker
Staging 0.055
Recurrence
ııı B or ıV 
Histology 0.074
Adenocarcinoma 
Non-adenocarcinoma 
Line 0.470
First-line setting
Later-line setting
Table 4.  Relationship between clinicopathologic features, gefitinib trough concentration and 
progression-free survival. *P <  0.05; aLog-rank test.
Figure 1. PFS of patients with Ctrough < 200 ng/ml (solid line) or Ctrough ≥ 200 ng/ml (dashed line). 
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higher number of mutations per Mb (mutations per Mb: median 10.5, range 4.9–17.6) compared to 
never-smokers with lung cancer (mutations per Mb: median 0.6, range 0.6–0.9)16. The differences in 
mutation frequencies and the distinctive sets of mutations may contribute to potential difference in the 
predictive and/or prognostic significance according to smoking history. Future investigations into the 
predictive difference by smoking history may lead to the optimization of current targeted therapy and 
detailed mechanism researches about the eruption of smoking-related lung cancer are of great value for 
cancer therapy.
As a targeted therapy agent, the tolerability profile of gefitinib is better than previous cytotoxic agents, 
and the most common adverse events include rash, diarrhea, nausea and hepatotoxicity. Although 
Yuanyuan Zhao et al. found that in EGFR wide-type patients, those with Ctrough  ≥ 200 ng/ml suffered 
more rash than with Ctrough < 200 ng/ml17. In our research, trough concentration was not significantly 
associated with skin rash, diarrhea and hepatotoxicity in patients with EGFR sensitive mutations. To 
date, some studies have shown that the mechanisms of these adverse effects are considerably complex and 
need to be answered18–21. In terms of cutaneous toxicities, no significant correlation were seen between 
dose levels and EGFR signaling pathway inhibition in skin biopsies9. What’s more, the eruption of cuta-
neous adverse drug reaction results from not only the inhibition of EGFR pathway, which acts as an 
initiation stage and leads to abnormal proliferation, migration, and differentiation of keratinocytes22, but 
also the disruption of the integrity of the skin with the recruitment of inflammatory cells23. In conclusion, 
the blood concentration, in itself, is not enough to account for the interindividual variability of adverse 
drug reaction, indicating that it is the tissue specific concentration that results in related toxicity.
This research has some limitations. This type of study retrospectively analyzed heterogeneous data 
with regard to patient cohort and follow-up pattern, meaning that the study results seem speculative, 
not definitive. Therefore, our results should be interpreted cautiously. In addition, to date, a number of 
somatic mutations in the EGFR gene have been identified that are associated with increased activity of 
EGFR tyrosine kinase inhibitors, and inherited polymorphisms in the EGFR gene have been associated 
with altered EGFR expression or function, future study should consider all these factors in the enrolled 
subjects.
In conclusion, our retrospective analysis suggests that, under standard-dose gefitinib, patients with 
lower trough concentration may be clinically equivalent to patients with higher trough concentration for 
NSCLC patients with EGFR sensitive mutations. In NSCLC patients with EGFR mutation under the dos-
age of 250 mg/day, gefitinib PKs and its clinical outcome were not closely correlated. Thus, dose reduc-
tion is a rational suggestion for adjustment of dose schedule. Prospective clinical trials to clarify and 
explore the precision dose schedule for patients with EGFR sensitive mutation are warranted. Meanwhile, 
non-smokers enjoyed better progression free survival for this specific group of NSCLC patients.
Figure 2. PFS of patients with non-smokers (solid line) or smokers (dashed line). 
Ctrough
Grade 0 V 1+ Grade 0 to 1 V 2+
OR 95% CI P OR 95% CI P
Rash 0.921 0.300–2.826 0.885 0.851 0.296–2.442 0.764
Diarrhea 1.461 0.488–4.377 0.498 0.974 0.083–11.435 0.983
Hepatotoxicity 1.111 0.332–3.715 0.864 0.301 0.034–2.640 0.279
Table 5.  The correlation between gefitinib trough concentration and toxicity.
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Material and methods
Subjects. The main patient entry criteria included: age ≥ 18 years; histologically and cytologically 
proved NSCLC; Eastern cooperative oncology group performance status (ECOG PS) ≤ 2; adequate 
hematological, renal and hepatic functions; direct sequencing and Real-time PCR proved EGFR sensi-
tive mutations.
Main exclusion criteria were as follows: uncontrolled systemic disease, any evidence of clinically active 
interstitial lung diseases, and other chemotherapy at the time of inclusion. The protocol was approved 
by the Ethical Committee of Cancer Center of Sun Yat-Sen University (CCSU), and written informed 
consent was obtained from each patient. The methods were carried out in accordance with the approved 
guidelines. This trial was registered with ClinicalTrials.gov, number NCT01994057 (date of registration: 
2013/11/23).
BSA was calculated as follows: BSA (m2) = (body weight [kg]) 0.425 × (height [cm]) 0.725 × 0.007184
Drug administration and disease assessment. Patients were treated with gefitinib monotherapy, 
250 mg/day, until progression. Before study entry and prior to each subsequent treatment cycle (the first 
duration cycle is one month, then the rest of intervals for tumor reassessment are two months), routine 
laboratory tests (hematology and biochemistry assessments) and full tumor assessment with computed 
tomography (CT) scans or magnetic resonance imaging (MRI) scans were performed by the investiga-
tor and radiologists according to the response evaluation criteria in solid tumors [RECIST]. Objective 
responses (complete response or partial response [PR]) were confirmed 4 or more weeks after responses 
were first observed, stable disease [SD] was confirmed 4 weeks after responses were first observed. CNS 
metastases were recorded as progression disease. Adverse events (AEs) were recorded, graded for toxicity 
using the NCI-CTC, and assessed by the investigator.
Detection of trough concentration and EGFR mutation. Plasma samples (2 mL) were collected 
on days 28 prior to drug administration, first tumor and toxicity assessment, frozen at − 80 °C until 
analysis. The steady state trough concentration was analyzed with validated high-performance liquid 
chromatographic method with tandem mass spectrometric (LC-MS/MS)24. Details of the assay and par-
tial validation data were included in the Supplementary material. EGFR mutation analysis was conducted 
using a primary tumor, metastatic lesion, such as lymph mode metastasis, or pleural effusion. EGFR 
mutation status was assessed by direct sequencing and real-time PCR (RT-PCR).
Statistical analysis. Pharmacokinetic parameters were characterized by the use of descriptive statis-
tics. The plasma gefitinib trough concentration (minimum steady-state concentration) was categorized 
into two groups: ‘low’ (trough concentration < 200 ng/ml) and ‘high’ (trough concentration ≥ 200 ng/ml). 
This trough concentration cutoff value was selected based on published data showing that a mean trough 
concentration of 0.40 μ M (178.76 ng/ml) was achieved following oral dosing with gefitinib 250 mg9. 
Meanwhile, the cutoff value was validated by X-tile 3.4.7 independently25. Patients were further stratified 
according to gender (male versus female), smoking history (never vs. ever), tumor histology (adeno-
carcinoma versus non-adenocarcinoma), development of diarrhea or skin rash (yes vs. no) and trough 
concentration (‘high’ vs. ‘low’). The association between the potential predictive factors and trough con-
centration was analyzed by Spearman rank correlation test. Potential predictive factors were tested in 
univariate models (with chi-square tests or the Fisher exact test) to predict response to gefitinib. Kaplan–
Meier analysis was used to estimate patient survival outcome. The log-rank test was used to compare the 
survival of patients with different predictive factors. Each analysis was two-sided, with a 5% significance 
level and a 95% confidence interval, and was performed with SPSS 13.0 for Windows software.
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